Becoming a Patient Advocate After Survivorship

People say "I want to give something back" and are usually pointed at a fundraising walk. The field is considerably wider than that, and the versions differ enough that being suited to one says nothing about the others.

Self-advocacy is managing your own care: asking for second opinions, requesting molecular profiling, questioning a plan. Organisational advocacy is volunteering with a charity or hospital — helpline work, patient and family advisory councils, information review, awareness campaigns. Research advocacy means contributing the patient perspective to how science gets funded and designed. Policy advocacy is legislative and regulatory work: access to drugs, coverage rules, screening programmes, employment protections, research budgets.

This is the most structured route and the least visible from outside.

Grant review is one entry point. Research funders run consumer review panels in which patient advocates sit alongside scientific reviewers and score applications for relevance and likely impact on people with the disease. The Congressionally Directed Medical Research Programs in the United States have used consumer reviewers in cancer research funding decisions for decades, and NCI's own advocate programme has published on how survivors participate in peer review. Advocates in these settings are not observers; they score, and their scores count.

Trial design is another. Cooperative groups that run multi-centre cancer trials, such as NRG Oncology, maintain formal patient advocate committees whose members sit on disease-site committees and comment on eligibility criteria, visit burden, endpoints that matter to patients, and the readability of consent forms. Institutional review boards and research ethics committees also require non-scientist community members, and cancer centres often recruit locally.

What these roles require is enough scientific vocabulary to participate in the conversation. That is what advocate science training programmes provide — typically several days covering cancer biology, trial design, statistics and how research funding works. Several are competitive, free to attend, and run by patient organisations rather than by industry.

Policy advocacy tends to start with a specific grievance — a drug not covered, a screening interval, a benefits rule — and grows from there. Large cancer charities run organised campaigning arms, including training for volunteers who meet legislators, and this is usually the fastest route in for someone without existing political experience.

Organisational volunteering is the most accessible starting point overall. Hospital patient and family advisory councils, charity information review panels, and disease-specific organisations all recruit people who have been through treatment, and most provide induction and supervision.

Most of this is unpaid. Some panels pay honoraria and cover travel; a minority of large organisations employ people in patient engagement, policy or navigation roles. The unpaid norm shapes who can afford to participate, which in turn shapes whose priorities reach the table — worth naming rather than ignoring.

Conflicts of interest matter more than newcomers expect. Advocates are routinely asked to disclose funding, travel support and organisational affiliations, and many patient organisations receive industry funding. Knowing where the money comes from, and being willing to say so, is part of doing this credibly.

Representation is a live issue too. Advocate cohorts skew towards people with more time, more education and better outcomes, and the people whose experience is most missing from research design are often those least able to volunteer for it.

This work means sustained contact with your own disease. Grant panels discuss mortality data for your cancer type. Committees discuss trials for people at the stage you were at. Communities you join will lose members, sometimes people you know well.

Some people find that manageable and even settling. Others find it reopens things they had put down, and stopping is a reasonable response rather than a failure. Boundaries set in advance — how many hours, which topics, which committees, what you will not read — hold better than boundaries improvised later.

And there is no obligation here at all. Survival does not generate a debt, and advocacy taken on as repayment tends to become an obligation that can never be discharged.

• NRG Oncology Patient Advocate Committee
• Congressionally Directed Medical Research Programs: Peer Reviewed Cancer Research Program (consumer reviewers)
• Supporting cancer survivors' participation in peer review: perspectives from NCI's CARRA program (PubMed)
• NCI Central IRB